2-氨基-4-氰基嘧啶 | 36314-98-4

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-氨基-4-氰基嘧啶
• 中文别名: 2-氨基-4-嘧啶甲腈
• 英文名称: 2-aminopyrimidine-4-carbonitrile
• 英文别名: 2-amino-4-cyanopyrimidine
• CAS: 36314-98-4
• 化学式: C₅H₄N₄
• mdl: MFCD09834971
• 分子量: 120.114
• InChiKey: KOTOJHBUFJPGEG-UHFFFAOYSA-N

物化性质

• 熔点：
  222 °C (decomp)
• 沸点：
  387.9±34.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  2-氨基-4-氰基嘧啶 在 氨 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、3.25 MPa 条件下， 反应 22.0h， 以92%的产率得到4-(氨甲基)-2-嘧啶胺
  参考文献：
  名称：

  [EN] 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES
  [FR] 3-AMINO -1,5,6,7-TÉTRAHYDRO-4 H-INDOL-4-ONES

  摘要：

  式(I)的化合物是Bub1激酶的抑制剂，其制备方法及其作为药物的用途。

  公开号：

  WO2015193339A1
• 作为产物：
  描述：

  2-氨基-4,6-嘧啶二甲腈 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 甲醇 为溶剂， 反应 18.0h， 以23%的产率得到2-氨基-4-氰基嘧啶
  参考文献：
  名称：

  Efficient Synthesis of Pyrimidinecarbonitriles and Their Derivatives

  摘要：

  New approach to pyrimidinecarbonitriles was developed. Pyrimidine-4- and 6-carbonitriles were prepared by palladium-catalyzed cross-coupling reaction of iodopyrimidines with Zn(CN)2 in very good yields. The cyano group was converted into the corresponding acyl groups by the treatment with Grignard reagents and transformed to amido and imido function as well.

  DOI：

  10.3987/com-07-11014

文献信息

• [EN] OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] INHIBITEURS OXADIAZOLE DE PRODUCTION DE LEUCOTRIÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012040137A1

  公开（公告）日：2012-03-29

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)的化合物及其药用盐，其中R1-R5如本文所定义。该发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的方法以及在这些过程中有用的中间体。
• Synthesis of (2-Aminopyrimidin-4-yl)(pyridin-4-yl)methanone and Derivatives
  作者：Francis Giraud、Fabrice Anizon、Pascale Moreau、Béatrice Josselin、Sandrine Ruchaud

  DOI：10.1055/a-2107-4571

  日期：2023.11

  Pyrido[3,4-g]quinazoline was previously identified as a relevant scaffold for protein kinase inhibition. In order to assess if the planarity of this heterocyclic system was essential to the protein kinase inhibitory potency observed in this series, new compounds were synthesized and evaluated, in which the central cycle was opened to provide (pyridin-4-yl)(pyrimidin-4-yl)methane derivatives, which were prepared from the corresponding ketone precursor. After preparing (2-aminopyrimidin-4-yl)(pyridin-4-yl)methanone, derivatives were synthesized and evaluated toward a panel of protein kinases. The results demonstrated that the planar pyrido[3,4-g]quinazoline tricyclic system was mandatory to maintain the protein kinase inhibitory potency in this series.

  摘要吡啶并[3,4-g]喹唑啉先前被确定为抑制蛋白激酶的相关支架。为了评估该杂环系统的平面性是否对该系列中观察到的蛋白激酶抑制效力至关重要，我们合成并评估了新的化合物，其中中心循环被打开，以提供(吡啶-4-基)(嘧啶-4-基)甲烷衍生物，这些衍生物是由相应的酮前体制备的。在制备出（2-氨基嘧啶-4-基）(吡啶-4-基)甲酮后，合成了衍生物并对一组蛋白激酶进行了评估。结果表明，平面吡啶并[3,4-g]喹唑啉三环系统是该系列保持蛋白激酶抑制效力的必要条件。
• Synthesis and structure–activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors
  作者：Andreas Reichelt、Julie M. Bailis、Michael D. Bartberger、Guomin Yao、Hong Shu、Matthew R. Kaller、John G. Allen、Margaret F. Weidner、Kathleen S. Keegan、Jennifer H. Dao

  DOI：10.1016/j.ejmech.2014.04.013

  日期：2014.6

  The Cell division cycle 7 (Cdc7) protein kinase is essential for DNA replication and maintenance of genome stability. We systematically explored thiazole-based compounds as inhibitors of Cdc7 kinase activity in cancer cells. Our studies resulted in the identification of a potent, selective Cdc7 inhibitor that decreased phosphorylation of the direct substrate MCM2 in vitro and in vivo, and inhibited DNA synthesis and cell viability in vitro.
• [EN] HETEROCYCLIC INHIBITORS OF EGFR AND/OR HER2, FOR USE IN THE TREATMENT OF CANCER<br/>[FR] MÉTHODES DE TRAITEMENT DU CANCER
  申请人：SCORPION THERAPEUTICS INC

  公开号：WO2022076831A3

  公开（公告）日：2022-07-07
• Nitrogen-Containing Heterocyclic Compound, Pharmaceutical Compositions thereof and Use thereof
  申请人：280 Bio, Inc.

  公开号：US20240158408A1

  公开（公告）日：2024-05-16

  Disclosed is a nitrogen-containing heterocyclic compound, pharmaceutical compositions thereof and use thereof. The present disclosure provides a nitrogen-containing heterocyclic compound represented by formula I, a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of pharmaceutically acceptable salt thereof, a crystal thereof, a stereoisomer thereof, a tautomer thereof or an isotopically labeled compound thereof. The nitrogen-containing heterocyclic compound represented by formula I is expected to treat and/or prevent various PI3K-meditated diseases.